NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage
biopharmaceutical company focusing on the development of innovative cancer therapies, today announced that the Company has filed
its annual report on Form 20-F for the fiscal year ended December 31, 2017 with the U.S. Securities and Exchange Commission on
April 03, 2018. The annual report can be accessed on the Company’s investor relations website at
http://ir.beyondspringpharma.com.
The Company will provide a hard copy of its annual report containing its audited consolidated financial statements, free of
charge, to its shareholders upon request. Requests should be directed to Investor Relations, BeyondSpring Inc., 28 Liberty
Street, 39th Floor, New York, NY 10005 USA.
About Plinabulin
Studies on Plinabulin's method of action indicate that Plinabulin activates GEF-H1, a guanine nucleotide exchange
factor. GEF-H1 activates downstream transduction pathways leading to the activation of the protein c-Jun. Activated c-Jun enters
the nucleus of dendritic cells to upregulate immune-related genes, which contributes to the up-regulation of a series of genes
leading to dendritic cell maturation, T-cell activation and other effects that prevent neutropenia.
About BeyondSpring
BeyondSpring is a global, clinical-stage biopharmaceutical company developing innovative immuno-oncology cancer
therapies with a robust pipeline from internal development and from collaboration with University of Washington in de novo drug
discovery using ubiquitination platform. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 global clinical trial as a direct
anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and two Phase 2/3 clinical programs in the prevention of
chemotherapy-induced neutropenia (CIN). BeyondSpring has a seasoned management team with many years of experience bringing drugs to
the global market.
Contact:
Media Relations:
Caitlin Kasunich / Amy Singh
KCSA Strategic Communications
212.896.1241 / 212.896.1207
ckasunich@kcsa.com / asingh@kcsa.com
Investor Relations:
Laura Perry / Joseph Rayne
Argot Partners
212.600.1902
BeyondSpring@argotpartners.com
